5-苯基-呋喃-2-甲醛肟 | 63191-69-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-苯基-呋喃-2-甲醛肟
• 英文名称: 5-phenyl-furan-2-carbaldehyde oxime
• 英文别名: 5-Phenyl-furan-2-carbaldehyd-oxim；2-Oximinomethyl-5-phenyl-furan；(NE)-N-[(5-phenylfuran-2-yl)methylidene]hydroxylamine
• CAS: 63191-69-5
• 化学式: C₁₁H₉NO₂
• mdl: MFCD00267502
• 分子量: 187.198
• InChiKey: GLCZLSZSLPOQPJ-XYOKQWHBSA-N

物化性质

• 沸点：
  328.8±30.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-苯基-呋喃-2-甲醛肟 在 盐酸 、 吡啶硼烷 作用下， 生成 N-(5-phenylfur-2-yl)methyl hydroxylamine
  参考文献：
  名称：

  Structure−Activity Relationships of N-Hydroxyurea 5-Lipoxygenase Inhibitors

  摘要：

  The discovery of second generation N-hydroxyurea 5-lipoxygenase inhibitors was accomplished through the development of a broad structure-activity relationship (SAR) study. This study identified requirements for improving potency and also extending duration by limiting metabolism. Potency could be maintained by the incorporation of heterocyclic templates substituted with selected lipophilic substituents. Duration of inhibition after oral administration was optimized by identification of structural features in the proximity of the N-hydroxyurea which correlated to low in vitro glucuronidation rates. Furthermore, the rate of in vitro glucuronidation was shown to be stereoselective for certain analogs. (R)-N-[3-[5-(4-Fluorophenoxy)-2-furyl]-1-methyl-2-propynyl]-N-hy- droxyurea (17c) was identified and selected for clinical development.

  DOI：

  10.1021/jm9700474
• 作为产物：
  描述：

  5-苯基-2-糠醛 在 盐酸羟胺 、 sodium acetate 作用下， 以 乙醇 、 水 为溶剂， 反应 3.5h， 生成 5-苯基-呋喃-2-甲醛肟
  参考文献：
  名称：

  Pong; Pelosi Jr.; Wessels, Arzneimittel-Forschung/Drug Research, 1983, vol. 33, # 10, p. 1411 - 1416

  摘要：

  DOI：

文献信息

• [EN] PYRIDAZINE DERIVATIVES FOR INHIBITING BETA AMYLOID PEPTIDE PRODUCTION<br/>[FR] DÉRIVÉS DE PYRIDAZINE POUR INHIBER LA PRODUCTION DE PEPTIDE BÉTA AMYLOÏDE
  申请人：GLAXO GROUP LTD

  公开号：WO2009050227A1

  公开（公告）日：2009-04-23

  The present invention relates to novel compounds that inhibit the production of β- amyloid peptide (1-42), processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease.

  本发明涉及抑制β-淀粉样肽（1-42）产生的新化合物，其制备方法，含有这些化合物的组合物，以及它们在治疗由高β-淀粉样蛋白水平或β-淀粉样蛋白沉积特征的疾病中的用途，特别是阿尔茨海默病。
• [EN] SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER<br/>[FR] COMPOSES SYNTHETIQUES ET DERIVES DE CEUX-CI EN TANT QUE MODULATEURS DE FUMEE OU D'INGESTION DE NICOTINE ET DU CANCER DU POUMON
  申请人：HUMAN BIOMOLECULAR RES INST

  公开号：WO2005066162A1

  公开（公告）日：2005-07-21

  Disclosed are nicotine-related compounds that selectively inhibit cytochrome P-450 2A6 (CYP2A6), selectively inhibit cytochrome P-450 2A13 (CYP2A13), and/or selectively modulate a nicotinic acetylcholine receptor (nAChR). Also disclosed are pharmaceutical compositions comprising a compound of the invention, as well as methods of using the pharmaceutical compositions for treating or preventing a disease or disorder associated with nicotine-ingestion, or a disease or disorder amenable to treatment by selective modulation of nAChRs.

  本公开了与尼古丁相关的化合物，其选择性地抑制细胞色素P-450 2A6（CYP2A6），选择性地抑制细胞色素P-450 2A13（CYP2A13），和/或选择性地调节尼古丁型乙酰胆碱受体（nAChR）。还公开了包含本发明化合物的药物组合物，以及使用这些药物组合物治疗或预防与尼古丁摄入相关的疾病或紊乱，或者通过选择性调节nAChRs治疗的疾病或紊乱的方法。
• Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer
  申请人：Cashman John R.

  公开号：US20080188527A1

  公开（公告）日：2008-08-07

  Disclosed are nicotine-related compounds that selectively inhibit cytochrome P-450 2A6 (CYP2A6), selectively inhibit cytochrome P-450 2A13 (CYP2A13), and/or selectively modulate a nicotinic acetylcholine receptor (nAChR). Also disclosed are pharmaceutical compositions comprising a compound of the invention, as well as methods of using the pharmaceutical compositions for treating or preventing a disease or disorder associated with nicotine-ingestion, or a disease or disorder amenable to treatment by selective modulation of nAChRs.

  本发明涉及选择性抑制细胞色素P-450 2A6（CYP2A6）、选择性抑制细胞色素P-450 2A13（CYP2A13）和/或选择性调节尼古丁乙酰胆碱受体（nAChR）的尼古丁相关化合物。本发明还涉及包含本发明化合物的制药组合物，以及使用该制药组合物治疗或预防与尼古丁摄入相关的疾病或障碍，或可通过选择性调节nAChR进行治疗的疾病或障碍的方法。
• SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER
  申请人：Cashman John R.

  公开号：US20100298345A1

  公开（公告）日：2010-11-25

  Disclosed are nicotine-related compounds that selectively inhibit cytochrome P-450 2A6 (CYP2A6), selectively inhibit cytochrome P-450 2A13 (CYP2A13), and/or selectively modulate a nicotinic acetylcholine receptor (nAChR). Also disclosed are pharmaceutical compositions comprising a compound of the invention, as well as methods of using the pharmaceutical compositions for treating or preventing a disease or disorder associated with nicotine-ingestion, or a disease or disorder amenable to treatment by selective modulation of nAChRs.

  本发明涉及选择性抑制细胞色素P-450 2A6（CYP2A6）的尼古丁相关化合物，选择性抑制细胞色素P-450 2A13（CYP2A13），和/或选择性调节尼古丁乙酰胆碱受体（nAChR）。本发明还涉及包含本发明化合物的制药组合物，以及使用该制药组合物治疗或预防与尼古丁摄入有关的疾病或障碍，或者通过选择性调节nAChRs进行治疗的疾病或障碍的方法。
• SOME ADDITION AND CYCLIZATION REACTIONS OF 1,4-DIBENZOYL-1,3-BUTADIENE¹
  作者：PHILIP S. BAILEY、WAFAI W. HAKKI、HOWARD W. BOST

  DOI：10.1021/jo01365a014

  日期：1955.8